Your 23andMe Colorectal Cancer Polygenic Report: What “Increased Likelihood” Really Means

Your 23andMe Colorectal Cancer Polygenic Report: What “Increased Likelihood” Really Means

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: A 23andMe “increased likelihood” result on the Colorectal Cancer Polygenic Report is a population-level statistic, not a diagnosis. A 2024 study in Nature Genetics traced 170 known colorectal cancer risk regions down to 208 candidate genes. That shows how much biology sits behind one polygenic number. That is very different from a single mutation with a clear inheritance pattern, the kind behind Lynch syndrome and MUTYH-associated polyposis. Right now, no major US screening guideline treats a polygenic score as a reason to change a colonoscopy schedule.

What you’ll learn:

• Why a polygenic score adds up thousands of small effects, not one gene
• How this differs from a monogenic (single-gene) syndrome like Lynch syndrome or MUTYH-associated polyposis
• What 23andMe’s own disclosed limits — including ancestry restrictions — mean for your result
• Why “increased likelihood” does not yet change screening guidelines, and what does

1. What a Polygenic Score Actually Is

A polygenic score is not a single result, the way a pregnancy test is. It is a sum. Researchers add up the small effects of thousands of common gene variants scattered across your genome. The total becomes one number that shows your background risk compared with other people.

The 23andMe Colorectal Cancer Polygenic Report is a direct-to-consumer (DTC) test, meaning it is ordered online by the customer rather than by a doctor. That matters because a DTC score works very differently from how most people picture “a genetic mutation for cancer.” A single-gene mutation, like the ones behind Lynch syndrome, is one exact error in one gene. That one error can raise risk on its own. A polygenic score works more like a neighborhood’s average commute time. No single street explains it, but thousands of small streets add up to a pattern.

A 2024 study in Nature Genetics mapped this pattern in detail for colorectal cancer (CRC). The researchers fine-mapped 170 known CRC risk regions. These had already been found through genome-wide association studies (GWAS). GWAS are large studies that scan the DNA of thousands of people to spot variants linked to a condition. Using colon-tissue chemical markers, they narrowed down which exact variants in each region were most likely doing the work. For 40 of the 170 regions, they pinpointed one variant as the most likely cause. They then linked these variants to 208 candidate target genes. They used colon gene-activity data and a model of how DNA on/off switches reach genes at a distance.

Several of the strongest signals cluster near the gene SMAD7 and a stretch of chromosome 8 called the 8q24 “gene desert.” This region has no genes of its own, but it holds on/off switches that influence nearby cancer-related genes. Researchers tested some of these switches directly in the lab. They used a technique that checks thousands of DNA snippets at once for their ability to turn nearby genes on or off.

Picture a kitchen scale with thousands of grains of sand scattered across both sides. No single grain tips the balance. Move a few hundred grains from one side to the other, though, and the reading shifts. Each common variant in a polygenic score works like one grain. A single-gene mutation, by contrast, is more like dropping one heavy stone onto the scale — big enough to see on its own.

The 2024 study did not discover these 170 regions from scratch. It took the existing, already-known list and worked out which genes within each region were doing the biological work. That is a finer, more detailed map than before, not a new discovery of risk locations.

The takeaway: a 23andMe result reflects contributions from potentially hundreds of these small-effect regions. It is not one gene with a name and a known inheritance pattern. That difference is the single most important thing to understand about a polygenic report.

Section recap: A polygenic score adds up thousands of small genetic effects into one number. It is not one mutation with a set inheritance pattern. A board-certified genetic counselor (searchable through NSGC.org) can walk through your report with you.

2. Why This Is Different From Lynch Syndrome or MUTYH-Associated Polyposis

A common source of confusion looks like this. A sibling tests negative for Lynch syndrome on a clinical multi-gene panel, while a different family member’s direct-to-consumer report comes back “increased likelihood.” These are not two versions of the same thing. They sit at opposite ends of what researchers call the spectrum of how genes cause disease. At one end is one powerful gene; at the other are thousands of small ones.

Lynch syndrome is caused by a single mutation — a monogenic, or one-gene, cause — in one of several mismatch-repair genes: MLH1, MSH2, MSH6, PMS2, or EPCAM. Mismatch-repair genes normally fix small copying errors in DNA; when one of them is broken, errors build up faster than usual. Lynch syndrome is inherited in an autosomal dominant pattern, meaning one copy of the mutation from either parent is enough to raise risk a lot. A “carrier” of a Lynch mutation has that one copy and is already at higher risk. Dominant conditions do not need a second copy to matter.

A large cohort study tracking carriers found that lifetime CRC risk to age 75 varies a lot by which gene is involved. Risk is highest for MLH1 and MSH2 carriers, and lower for MSH6 and PMS2 carriers. Because the risk is gene-specific and well measured, clinical guidelines can assign exact colonoscopy schedules to each gene.

MUTYH-associated polyposis (MAP) works differently. It requires two mutations, one inherited from each parent, in a DNA-repair gene called MUTYH. That is an autosomal recessive pattern. Here, “carrier” means something different: a person with only one MUTYH mutation is usually not at high risk. It takes two copies to raise risk sharply. Genetics references estimate that two-copy (biallelic) MUTYH mutations explain roughly 1% of all CRC cases. Two-copy carriers still face a high, well-measured lifetime risk tied to how many polyps they build up. Because the pattern is recessive and well defined, siblings of a two-copy carrier can be offered targeted “cascade” testing to check their own status.

A polygenic score describes something else. It is the common, additive background risk behind most colorectal cancer cases — the ones not explained by any single high-penetrance gene. “High-penetrance” means a gene whose mutations make the disease highly likely to develop, the way Lynch syndrome and MUTYH mutations do. The National Cancer Institute’s genetics summary puts this in perspective. Hereditary syndromes like Lynch syndrome and MAP together account for roughly 5-6% of all CRC cases. Most cases arise from this polygenic, non-hereditary background instead.

A negative monogenic panel test does not rule out polygenic background risk in the same family. And a polygenic report in one relative does not imply a hidden monogenic mutation that a panel test missed. A multi-gene panel looks for named errors. A polygenic score never looks for any single error. It only measures the combined weight of many ordinary variants everyone carries in some mix.

The table below lays out the three types of result side by side.

	Lynch syndrome	MUTYH-associated polyposis (MAP)	Polygenic score (this report)
Gene(s)	MLH1, MSH2, MSH6, PMS2, EPCAM	MUTYH (two copies)	Thousands of common variants genome-wide
Inheritance	Autosomal dominant — one copy is enough	Autosomal recessive — needs one copy from each parent	No single pattern; each variant inherited independently
Share of CRC cases	Part of the ~5-6% from known hereditary syndromes	About 1% of all CRC cases	Underlies most of the remaining, non-hereditary cases
What a result means	A confirmed, gene-specific risk level	A confirmed, gene-specific risk level	A shift in population odds, not a fixed number
Typical next step	Gene-specific colonoscopy schedule	Early, frequent colonoscopy	Standard age-appropriate screening; no separate schedule yet

Section recap: Lynch syndrome and MUTYH-associated polyposis are single-gene, high-penetrance conditions with a set inheritance pattern; a polygenic score is not. A genetic counselor can help a family sort out which type of result applies to which relative.

3. What “Increased Likelihood” Actually Means, Numerically

23andMe states, in its own product materials, that only 5-30% of eligible members receive an “increased likelihood” result at all. That range depends on cancer type and ancestry. That is a wide range. It exists because how much a polygenic score shifts someone’s risk depends on which variants a person carries. It also depends on how well the score was calibrated for people like them.

Here is what 23andMe discloses about this report, in its own words:

• 5-30% of eligible members receive an “increased likelihood” result, depending on cancer type and ancestry.
• The Colorectal Cancer Polygenic Report is currently offered only to customers of European or Latino/Hispanic ancestry.
• 23andMe is running a separate study, called “Genetic insights into colorectal cancer in the Black community,” to improve accuracy for customers of African ancestry.

That ancestry limit reflects a broader, well-known pattern in the field, not something unique to 23andMe. Most large CRC genome-wide studies have historically enrolled participants who are mostly of European ancestry. That skew limits how accurately a resulting score applies to people from other backgrounds. Readers of African ancestry may not yet have access to a calibrated result at all, based on 23andMe’s own disclosure.

For context, the lifetime risk of a colorectal cancer diagnosis is about 4.1% for men (roughly 1 in 24) and 3.8% for women (roughly 1 in 26). An “increased likelihood” result shifts that baseline upward for the group you belong to. It does not replace it with a new, fixed number.

What does “increased likelihood” mean once you have it? It is a statement about a shift in the odds for a group of people, not a fixed percentage. It is not the same as being told “your lifetime risk is X%,” the way some single-gene results can be quoted. Think of it less like a thermometer reading and more like a weather forecast that shifts from “30% chance of rain” to “45% chance of rain.” That is a useful clue about tilted odds. It is not a guarantee of what happens on any single day.

What determines any one person’s score is which variants they inherited from each parent — almost at random — at each of the thousands of locations involved. Two siblings can inherit different combinations from the same parents. That is one reason polygenic results can differ between relatives even when family history looks similar.

This is also why an “average” or “not increased” result deserves the same caution in the other direction. It does not mean zero risk. It only means this score did not detect a meaningful upward shift for your ancestry group. Colorectal cancer still occurs in people without any flagged polygenic result. That is why age-appropriate screening applies to nearly everyone, not only to people with an “increased likelihood” report.

Section recap: 23andMe’s own disclosure shows this report flags 5-30% of eligible members as increased-likelihood. Access is now limited to European and Latino/Hispanic ancestry. A primary care doctor or genetic counselor can help put a report in personal context.

4. Comparing Your Testing Options

People researching a colorectal cancer result often run into three different kinds of tests, and mixing them up is a common source of confusion.

1. Direct-to-consumer (DTC) polygenic reports, like the 23andMe Health Predisposition Colorectal Cancer Polygenic Report, are consumer-purchased and estimate aggregate, population-level risk. They are not diagnostic and are not ordered by a doctor.

2. Clinical multi-gene hereditary-cancer panel testing is ordered by a doctor or genetic counselor through a clinical laboratory. It looks for pathogenic variants in certain genes: the Lynch syndrome genes, APC, MUTYH, and others. When ordered for a documented family-history reason, it is often billable to insurance.

3. Diagnostic and screening tests for colorectal cancer itself include stool-based tests — the fecal immunochemical test (FIT) and FIT-DNA tests such as Cologuard — plus colonoscopy. These remain the only ways to find or rule out polyps and cancer in the colon, regardless of any genetic result.

A polygenic report cannot substitute for either of the other two. It does not replace a clinical panel test when family history meets referral criteria under established guidelines. It also does not replace age-appropriate screening, since only a direct look at the colon can find a polyp before it turns into cancer.

The table below compares the three side by side.

Pathway	Who orders it	What it tells you	Typical cost
DTC polygenic report (e.g., 23andMe)	You, directly, online	A shift in population-level odds — not a diagnosis	Flat, out-of-pocket consumer price
Clinical multi-gene panel	A doctor or genetic counselor	Whether a pathogenic variant is present or absent	Often billable to insurance with a qualifying family history
Colonoscopy or stool-based screening (FIT, FIT-DNA)	A doctor, as routine screening	Whether a polyp or cancer is present	Often no extra cost under ACA-compliant plans at recommended ages; check your plan

A simple way to keep the three straight: a polygenic report is a weather forecast for the population you belong to. A panel test is a named diagnosis, present or absent. Screening is the only one of the three that looks inside your colon.

The U.S. Preventive Services Task Force (USPSTF) gives colorectal cancer screening a Grade A rating for adults 50-75. It gives a Grade B rating for starting at 45. Approved options include colonoscopy, FIT, FIT-DNA, CT colonography, and flexible sigmoidoscopy. Under most ACA-compliant health plans, Grade A and B preventive services are often covered without extra cost. Billing for follow-up procedures can vary, so check with your plan.

Section recap: A DTC polygenic score, a clinical multi-gene panel, and colonoscopy-based screening answer three different questions, and none replaces the others. If your family history includes early-onset cancer, ask your doctor about a referral for clinical panel testing.

5. How to Interpret Your Result Clinically

An “increased likelihood” polygenic result is a statement about odds, not a diagnosis. It is not a diagnosis of cancer, a precancerous finding, or a prediction about your future. That distinction matters in practice.

Contrast it with a “variant detected” result on a monogenic panel test. A confirmed pathogenic variant in a Lynch syndrome gene, or in both copies of MUTYH, has a set clinical path. National guidelines specify earlier, more frequent colonoscopy schedules tailored to the gene involved. A polygenic “increased likelihood” result does not yet trigger any equivalent, guideline-set change in checkups.

That is not an oversight. It reflects where the evidence stands today. As of this writing, major US screening bodies have not built commercial polygenic risk scores into their formal screening-schedule advice. A review commissioned to inform the USPSTF’s most recent guideline update found no studies evaluating whether adding a polygenic score changes screening outcomes. In plain terms, a polygenic result is not, on its own, something your doctor can use right now to move up your next colonoscopy. A confirmed Lynch syndrome diagnosis would.

That may change. Fine-mapping work like the 2024 Nature Genetics study is the kind of foundational research a future guideline revision would need to draw on. But the most recent USPSTF evidence review found no studies yet testing whether adding a polygenic score changes screening outcomes. For now, the honest statement is “not yet used,” not “will never matter.”

Section recap: “Increased likelihood” is a shift in the odds, not a diagnosis. Current US guidelines do not yet use polygenic scores to set screening schedules. Bring your report to your doctor so it can be discussed alongside your personal and family history.

6. Prevention and Early Detection: What Actually Changes Your Risk

The single most important recent change in colorectal cancer prevention has nothing to do with polygenic scores. In 2021, the USPSTF lowered its recommended starting age for average-risk screening from 50 to 45. It issued a Grade B rating for that change, alongside its existing Grade A rating to screen adults 50 to 75.

That change responded to a real trend. Colorectal cancer incidence has been rising steadily in adults under 50 since the mid-1990s, even as it has declined in adults 65 and older. One major analysis found that people born around 1990 have roughly double the colon cancer risk of people born around 1950. Their rectal cancer risk is roughly quadruple. The same analysis projects the disease will become the leading cause of cancer death in Americans aged 20 to 49. That generational shift means colorectal cancer now makes up a bigger share of diagnoses in people under 50 than it did a generation ago. That is the reason the recommended screening age moved earlier rather than staying put. This trend is the likely backdrop for early-onset diagnoses in families with no prior cancer history.

Whatever a polygenic score shows, the concrete tools for lowering risk and catching disease early stay the same:

• Get screened on schedule — colonoscopy or a stool-based test (FIT or FIT-DNA), starting at 45 for most adults.
• Eat a diet with plenty of vegetables, fruit, and fiber, and less red or processed meat.
• Stay physically active.
• Avoid smoking.
• Limit alcohol.

An “increased likelihood” polygenic result is not, by itself, a guideline-backed reason to start screening before 45. The usual reasons for earlier screening remain symptoms, a strong family history, or a confirmed hereditary syndrome.

Think of it as two separate dials on the same dashboard. One dial is your background genetic risk, whether polygenic or single-gene. The other is your screening schedule, set by age, symptoms, and family history — not by a DTC report. The two dials are not wired together yet. Both matter, though, and adjusting one is not a substitute for keeping the other on schedule. If you are unsure which dial applies to you, a primary care doctor can help sort it out.

Section recap: The USPSTF’s 2021 move to start average-risk screening at 45 responds to a real rise in early-onset CRC. It does not respond to individual polygenic scores. Talk to your doctor about your own screening schedule rather than changing it based on a DTC report alone.

7. The Current Treatment Landscape for Advanced Disease

It’s worth understanding where real, dated medical progress against colorectal cancer is happening right now. It’s also worth being clear that this progress is separate from a polygenic risk score for someone who is healthy now.

In 2023, the FDA approved fruquintinib (brand name Fruzaqla, developed by Takeda and HUTCHMED) on November 8. The approval covers adults with metastatic colorectal cancer previously treated with standard chemotherapy and targeted therapies. Fruquintinib is an oral drug that blocks three related proteins — VEGFR-1, -2, and -3 — involved in the blood-vessel growth that tumors depend on.

The approval rested on the FRESCO-2 trial, an international, randomized, double-blind phase 3 study of 691 adults with previously treated metastatic disease. Patients receiving fruquintinib had a median overall survival of 7.4 months, compared with 4.8 months on placebo. That is a hazard ratio of 0.66. At any given point in the trial, patients on fruquintinib were about a third less likely to die than those on placebo. Health Canada followed with its own market approval for the same use on January 20, 2025. That approval drew on FRESCO-2 together with a companion China-based phase 3 trial, with reimbursement and provincial reviews following afterward.

Tumors need a blood supply to keep growing, the way a construction site needs a supply road. VEGFR-1, -2, and -3 are receptors that help the body build those roads toward a tumor. By blocking all three, fruquintinib is designed to cut off that supply route instead of attacking tumor cells directly. That is why it can still help even after other chemotherapy and targeted drugs have stopped working.

This is meaningful, dated progress for people already living with metastatic colorectal cancer. It has no bearing on a polygenic score, and it does not change screening or prevention advice for someone who has not been diagnosed. Anyone weighing treatment options should do so with an oncologist.

Section recap: Fruquintinib’s 2023 FDA approval and 2025 Health Canada approval are real progress in treating existing advanced disease. They do not change how anyone’s background risk score should be read. Questions about eligibility for a therapy belong with an oncologist, not a risk calculator.

8. Family Implications, Insurance, and the Emotional Side

A polygenic score is not one clear-cut variant. Because of that, it cannot be passed to a child in a predictable fraction the way a single dominant or recessive mutation can. There is no equivalent “cascade testing” recommendation — the practice of systematically testing first-degree relatives — built around a polygenic report alone. Family members are better guided by their own family cancer history and by starting age-appropriate screening on schedule.

Many readers ask about insurance first. The federal Genetic Information Nondiscrimination Act (GINA), enacted in 2008, protects results like a polygenic Health Predisposition report from being used against you:

• Title I bars group and individual health insurers from using genetic information, including polygenic results, in eligibility, coverage, or premium decisions.
• Title II bars employers with 15 or more employees from using genetic information in hiring, firing, or promotion decisions.
• The gap: GINA’s protections do not extend to life insurance, disability insurance, or long-term-care insurance underwriting.

Practically, this means a 23andMe polygenic report cannot lawfully raise your health-insurance premium or cost you your job. It is still reasonable to think twice before sharing detailed genetic results in a life insurance or long-term-care application. Those industries sit outside GINA’s protection. Some states add their own protections beyond GINA’s federal floor, especially for life insurance. It is worth checking your state’s insurance rules, or asking a genetic counselor, before assuming GINA is the whole picture.

Finally, it is worth naming the emotional weight in a family with mixed results. One sibling has a monogenic panel test that came back negative for a known high-risk syndrome. Another has an ancestry-restricted polygenic result flagging “increased likelihood.” These are two different kinds of genetic results. Making sense of them without help can be truly confusing. That confusion does not mean either person misread their result. A board-certified genetic counselor, found through the National Society of Genetic Counselors’ directory, specializes in exactly this kind of family situation.

Section recap: GINA protects health-insurance and employment decisions from polygenic results. It does not cover life, disability, or long-term-care insurance, and there is no set cascade-testing pathway for a polygenic score. A genetic counselor can help a family with mixed results make sense of what each one means.

Frequently Asked Questions

Will I get colorectal cancer because my 23andMe result says “increased likelihood”? No. It is a statement about shifted odds for a group, not a diagnosis. Colorectal cancer affects only a minority of people over a lifetime. So a shift in the odds still leaves most people with an increased-likelihood result free of the disease. Screening remains the tool that finds or prevents it.

Will my children inherit my increased polygenic risk? Not in a simple, predictable way. A polygenic score reflects thousands of variants with no set inheritance pattern, unlike a single Lynch syndrome or MUTYH mutation. Your children’s risk depends on which mix of those variants they happen to inherit from each parent, which is close to random at each spot. There is no cascade-testing pathway built for this kind of result.

Can this result affect my health or life insurance? Health insurance and employment decisions are protected under GINA. Life, disability, and long-term-care insurance are not covered by GINA. That could matter if you apply for one of those policies — worth discussing with an insurance professional if you have concerns.

Can my employer find out about my result? GINA’s Title II bars employers with 15 or more employees from using genetic information, including a polygenic report, in hiring, firing, or promotion decisions.

Should I get a second opinion or talk to a specialist? Yes. A board-certified genetic counselor or your primary care doctor can put a polygenic result in context alongside your personal and family history. A DTC report alone cannot do that. See the counselor directory linked earlier in this article.

Summary

A 23andMe “increased likelihood” result for colorectal cancer describes population-level risk built from thousands of common variants. A 2024 fine-mapping study mapped this in detail, linking risk regions to 208 candidate genes. It is very different from single-gene, high-penetrance syndromes like Lynch syndrome and MUTYH-associated polyposis. Those have a set inheritance pattern and guideline-specific checkup schedules.

The report carries limits that 23andMe discloses itself: a 5-30% increased-likelihood rate, and access limited to European and Latino/Hispanic ancestry. As of this writing, no major US screening guideline builds polygenic scores into checkup-schedule advice.

What reliably changes risk and outcomes stays the same regardless of a polygenic score. Age-appropriate colonoscopy or stool-based screening now starts at 45, given the real rise in early-onset disease. For people already facing advanced disease, real treatment progress continues, including fruquintinib’s 2023 FDA and 2025 Health Canada approvals. None of this replaces a conversation with your doctor or a board-certified genetic counselor about your own history.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. Fernandez-Rozadilla C, et al. “Systematic prioritization of functional variants and effector genes underlying colorectal cancer risk.” Nature Genetics, 2024. https://doi.org/10.1038/s41588-024-01900-w
2. Dasari A, et al. “Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.” The Lancet, 2023;402(10395):41-53. PMID 37331369. https://pubmed.ncbi.nlm.nih.gov/37331369/
3. U.S. Food and Drug Administration. FDA approval of fruquintinib (Fruzaqla) for previously treated metastatic colorectal cancer, 2023-11-08. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fruquintinib-previously-treated-metastatic-colorectal-cancer
4. Health Canada. Market authorization notice for FRUZAQLA (fruquintinib), metastatic colorectal cancer indication, 2025-01-20. https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
5. Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. “Colorectal Cancer Statistics, 2023.” CA: A Cancer Journal for Clinicians, 2023;73(3):233-254. https://doi.org/10.3322/caac.21772
6. Genetic Information Nondiscrimination Act (GINA), Public Law 110-233 (2008). https://www.eeoc.gov/genetic-information-discrimination
7. US Preventive Services Task Force. “Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement.” JAMA, 2021;325(19):1965-1977. https://doi.org/10.1001/jama.2021.6238
8. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment — Colorectal, Version 1.2024. https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1436
9. Nielsen M, et al. “MUTYH Polyposis.” GeneReviews (NCBI Bookshelf / NLM), updated 2021. https://www.ncbi.nlm.nih.gov/books/NBK107219/
10. Møller P, et al. “Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age.” Gut, 2018;67(7):1306-1316. https://doi.org/10.1136/gutjnl-2017-314057
11. Lin JS, Perdue LA, Henrikson NB, Bean SI, Blasi PR. “Screening for Colorectal Cancer: An Evidence Update for the US Preventive Services Task Force.” JAMA, 2021;325(19):1978-1998. https://doi.org/10.1001/jama.2021.4417
12. National Cancer Institute (NCI). “Genetics of Colorectal Cancer (Health Professional Version),” PDQ, 2024 revision. https://www.cancer.gov/types/colorectal/hp/colorectal-genetics-pdq
13. 23andMe, Inc. “23andMe Launches New Genetic Reports on Common Forms of Cancer” (Colorectal Cancer Polygenic Report, Powered by 23andMe Research), GlobeNewswire press release, 2024-03-06. https://www.23andme.com/gen-health-predisposition/
14. National Cancer Institute (NCI), Surveillance, Epidemiology, and End Results (SEER) Program. “Cancer Stat Facts: Colorectal Cancer.” https://seer.cancer.gov/statfacts/html/colorect.html

Last updated: 2026-09-24

Author: genelumen editorial team. This article aggregates 14 sources (tier 1=10 / tier 2=3 / tier 4=1), including the FDA, Health Canada, the NCI, USPSTF, NCCN, and 23andMe’s own product disclosures.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada) or 119 (Japan).

🌐 日本語版: https://genelumen.com/ja/ja-hereditary-cancer/colorectal-cancer-genetic-risk-polygenic-score-fap-map